NEW YORK, November 27, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timely
California headquartered Edwards Lifesciences Corp.'s stock finished last Friday's session 0.49% higher at $109.34. A total volume of 389,570 shares was traded. The Company's shares have advanced 5.82% in the past month and 16.69% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 1.07% and 1.58%, respectively. Additionally, shares of Edwards Lifesciences, which provides products and technologies to treat structural heart disease and critically ill patients worldwide, have a Relative Strength Index (RSI) of 60.37.
On October 31st, 2017 at the 29th Transcatheter Cardiovascular Therapeutics in Denver, Edwards Lifesciences announced new data demonstrating substantial economic advantages of the Edwards SAPIEN 3 transcatheter aortic heart valve for patients suffering from severe, symptomatic aortic stenosis, who are at intermediate risk for open-heart surgery. The analysis showed significantly lower total one-year costs, on average, with the SAPIEN 3 valve compared with surgical aortic valve replacement ($80,977 versus $96,489). Complimentary subscription to our free research report on EW at:
On Friday, shares in Pennsylvania headquartered Globus Medical Inc. ended the session 0.46% lower at $37.08. The stock recorded a trading volume of 194,217 shares. The Company's shares have gained 18.73% in the last one month, 27.20% in the previous three months, and 49.46% on an YTD basis. The stock is trading 17.39% above its 50-day moving average and 20.76% above its 200-day moving average. Moreover, shares of Globus Medicalhave an RSI of 70.53.
On November 10th, 2017, research firm Bank of America/ Merrill upgraded the Company's stock rating from 'Underperform' to 'Neutral'.
On November 20th, 2017, Globus Medical announced that management plans to participate in the Piper Jaffray 29th Annual Healthcare Conference on November 29th, 2017, at 10:00 a.m. ET at the Lotte New York Palace in New York City. An audio webcast of the presentation will be available under the Investor Relations page of the Company's website. Access the free research report on GMED now by signing up at:
Ohio headquartered Invacare Corp.'s shares gained 0.28%, closing the session at $17.90 with a total trading volume of 107,884 shares. The stock has gained 17.38% in the last one month, 35.61% over the previous three months, and 37.16% on an YTD basis. Shares of the Company are trading 14.39% and 30.17% above their 50-day and 200-day moving averages, respectively. Additionally, shares of Invacare, which together with its subsidiaries, designs, manufactures, distributes, and exports medical equipment for use in home health care, retail, and extended care markets worldwide, have an RSI of 66.33.
On November 16th, 2017, Invacare's Board of Directors declared a cash dividend of $.0125 per share on the Company's common shares and $.011364 per share on its Class B common shares, payable on January 16th, 2018, to shareholders of record on January 04th, 2018. Are you already registered with Wall St. Equities? Do so now for free, and get the report on IVC at:
Last Friday at the close, shares in Ireland headquartered Medtronic PLC recorded a trading volume of 3.17 million shares. The stock ended the session 1.11% higher at $83.25. The Company's shares have advanced 5.11% in the past month, 5.30% over the previous three months, and 16.87% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 5.11% and 1.22%, respectively. Furthermore, shares of Medtronic have an RSI of 66.24.
On November 20th, 2017, Medtronic announced the US FDA approval and US commercial launch for the Company's portfolio of AzureTM pacemakers with BlueSyncTM technology. Available in both single chamber and dual chamber models, the Azure XT MRI and Azure S MRI pacemakers offer improved longevity, estimated at 13.7 years (dual chamber) or 27% longer than its predecessor, so patients likely need fewer device replacements. The new pacemakers also allow patients to have MRI (magnetic resonance imaging) scans in either 1.5 or 3 Tesla machines.
On November 22nd, 2017, research firm Stifel reiterated its 'Hold' rating on the Company's stock with an increase of the target price from $83 a share to $85 a share. Aspiring Member, please take a moment to register below for your free research report on MDT at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +21-32-044-483 Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...
Urinary retention is a condition where a person is unable to voluntarily empty the urinary bladder ...View All